Alto Neuroscience (NYSE:ANRO) Trading Up 9.1% – Time to Buy?

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) traded up 9.1% during mid-day trading on Tuesday . The stock traded as high as $22.00 and last traded at $21.7950. 102,530 shares were traded during trading, a decline of 56% from the average session volume of 234,185 shares. The stock had previously closed at $19.98.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 target price on shares of Alto Neuroscience in a research note on Monday, March 16th. Wedbush lifted their price target on shares of Alto Neuroscience from $13.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 17th. Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Finally, BTIG Research raised their price objective on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.33.

Alto Neuroscience Trading Up 4.0%

The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69. The business has a fifty day simple moving average of $19.09 and a 200 day simple moving average of $14.63. The company has a market cap of $746.90 million, a P/E ratio of -10.72 and a beta of 2.52.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. Analysts anticipate that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new stake in shares of Alto Neuroscience during the first quarter worth $52,000. Torren Management LLC acquired a new position in shares of Alto Neuroscience in the 4th quarter valued at about $62,000. Invesco Ltd. bought a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $67,000. Vanguard Personalized Indexing Management LLC grew its position in shares of Alto Neuroscience by 13.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after buying an additional 2,055 shares during the last quarter. Finally, Bridgeway Capital Management LLC raised its stake in Alto Neuroscience by 85.9% during the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after acquiring an additional 25,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.